Search

Author/Creator Zimmerman, Todd

2. A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results. (26th October 2017)

Authors:
Spencer, Andrew; Harrison, Simon; Zonder, Jeffrey; Badros, Ashraf; Laubach, Jacob; Bergin, Krystal; Khot, Amit; Zimmerman, Todd; Chauhan, Dharminder; Levin, Nancy; MacLaren, Ann; Reich, Steven D.; Trikha, Mohit; Richardson, Paul
Journal:
British journal of haematology
Issue:
Volume 180:Number 1(2018)
Page Start:
41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. Issue 12 (6th October 2015)

Authors:
Kumar, Shaji K; Krishnan, Amrita; LaPlant, Betsy; Laumann, Kristina; Roy, Vivek; Zimmerman, Todd; Gertz, Morie A; Buadi, Francis K; Stockerl Goldstein, Keith; Birgin, Ann; Fiala, Mark; Duarte, Lupe; Maharaj, Michelle; Levy, Joan; Vij, Ravi
Journal:
American journal of hematology
Issue:
Volume 90:Issue 12(2015:Dec.)
Page Start:
1106
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Issue 1 (January 2021)

Authors:
Usmani, Saad Z; Hoering, Antje; Ailawadhi, Sikander; Sexton, Rachael; Lipe, Brea; Hita, Sandi Fredette; Valent, Jason; Rosenzweig, Michael; Zonder, Jeffrey A; Dhodapkar, Madhav; Callander, Natalie; Zimmerman, Todd; Voorhees, Peter M; Durie, Brian; Rajkumar, S Vincent; Richardson, Paul G; Orlowski...
Journal:
Lancet
Issue:
Volume 8:Issue 1(2021)
Page Start:
e45
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗